Polypill Reduces Cardiovascular Risk
Author Information
Author(s): Anthony Rodgers, Anushka Patel, Otavio Berwanger, Michiel Bots, Richard Grimm, Diederick E. Grobbee, Rod Jackson, Bruce Neal, Jim Neaton, Neil Poulter, Natasha Rafter, P Krishnam Raju, Srinath Reddy, Simon Thom, Stephen Vander Hoorn
Primary Institution: The George Institute for Global Health
Hypothesis
Can a Polypill Safely Halve Cardiovascular Risk?
Conclusion
The polypill achieved significant reductions in blood pressure and cholesterol but caused side effects in about 1 in 6 people.
Supporting Evidence
- The polypill reduced systolic blood pressure by 9.9 mmHg.
- LDL-cholesterol was reduced by 0.8 mmol/L.
- Discontinuation rates were 23% for the polypill group compared to 18% for placebo.
- 58% of the polypill group reported side effects compared to 42% in the placebo group.
- Most side effects were known issues related to the individual components of the polypill.
Takeaway
A special pill can help people with heart risks feel better by lowering their blood pressure and cholesterol, but some might feel sick from it.
Methodology
Randomised, double-blind placebo-controlled trial comparing a polypill to placebo over 12 weeks.
Potential Biases
Potential bias due to the relatively narrow participant demographics and the short duration of the study.
Limitations
Short follow-up period and the inability to definitively attribute side effects to specific components of the polypill.
Participant Demographics
Participants were adults aged 18 and older with a 5-year cardiovascular disease risk over 7.5%.
Statistical Information
P-Value
p=0.2
Confidence Interval
95% CI: 7.7 to 12.1 mmHg for SBP reduction; 95% CI: 0.6 to 0.9 mmol/L for LDL-cholesterol reduction.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website